{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["Q3-2022"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":0,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Q3-2022","index":0,"n_rows":127,"n_cols":9,"rows_kept":127,"cut":false,"hidden":false,"merged":[]}
["Therapeutic area","Project ","Phase ","NCT number ","Title","Conditions ","Enrollment","Study Design","Dates"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","• Chronic Obstructive Pulmonary Disease",924,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 1, 2023\nStudy Completion: October 20, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","• Bullous Pemphigoid",98,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 27, 2023\nStudy Completion: September 15, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","• Chronic Spontaneous Urticaria",384,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 15, 2024\nStudy Completion: June 7, 2024"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03930732","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","• Chronic Obstructive Pulmonary Disease",939,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 1, 2023\nStudy Completion: May 2, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","• Asthma",365,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2025\nStudy Completion: March 31, 2025"]
["Immuno-inflammation","Kevzara (anti-IL6 mAb) ","\nPhase 2\n","NCT02991469","A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","• Juvenile Idiopathic Arthritis",72,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2023\nStudy Completion: April 2027"]
["Immuno-inflammation","Kevzara (anti-IL6 mAb) ","\nPhase 2\n","NCT02776735","An Open-label, Ascending, Repeated Dose- finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)","• Juvenile Idiopathic Arthritis",100,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 8, 2022\nStudy Completion: December 28, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants #6 Months to <18 Years of Age With Atopic Dermatitis (AD)","• Atopic Dermatitis",880,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 19, 2026\nStudy Completion: August 19, 2026"]
["Immuno-inflammation","eclitasertib (RIPK1 inhibitor)","\nPhase 2\n","NCT04781816","Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus","• Cutaneous Lupus Erythematosus",88,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 13, 2023\nStudy Completion: July 15, 2023"]
["Immuno-inflammation","SAR444656 (IRAK4 degrader)","\nPhase 1\n","NCT04772885","A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)","• Healthy Volunteer\n• Atopic Dermatitis\n• Hidradenitis Suppurativa",202,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 30, 2022\nStudy Completion: December 30, 2022"]
["Immuno-inflammation","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)","• Chronic Obstructive Pulmonary Disease",1170,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 26, 2024\nStudy Completion: January 13, 2025"]
["Immuno-inflammation","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04701983","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","• Chronic Obstructive Pulmonary Disease",930,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 13, 2024\nStudy Completion: October 31, 2024"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04684524","Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)","• Allergic Fungal Rhinosinusitis",120,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 28, 2024\nStudy Completion: September 20, 2024"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04681729","Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","• Cold Urticaria",82,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 14, 2022\nStudy Completion: April 27, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04678856","Dupilumab in CRSsNP (Liberty CRSsNP ORION)","• Chronicrhinosinusitis Without Nasalpolyps\n• Sinusitis\n• Chronic Sinusitis\n• Sinus Disorder\n• Respiratory Disorder",240,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 31, 2023\nStudy Completion: May 30, 2024"]
["Immuno-inflammation","frexalimab (anti-CD40L mAb)","\nPhase 2\n","NCT04572841","Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)","• Sjögren's Syndrome",88,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 22, 2023\nStudy Completion: March 8, 2024"]
["Immuno-inflammation","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT04520451","Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients","• IgG4-Related Disease",25,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 1, 2023\nStudy Completion: December 5, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04442269","A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","• Allergic Bronchopulmonary Aspergillosis",170,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 26, 2023\nStudy Completion: December 21, 2023"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05492578","Long-Term Safety and Efficacy Evaluation of Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis","• Dermatitis Atopic",300,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 29, 2027\nStudy Completion: October 29, 2027"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05421598","Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma","• Asthma",420,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 4, 2024\nStudy Completion: March 21, 2025"]
["Immuno-inflammation","SAR443765 (Anti-IL13/TSLP Nanobody VHH)","\nPhase 1\n","NCT05366764","First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants","• Asthma",36,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: April 11, 2023\nStudy Completion: April 11, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT05263206","Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO- CHIC)","• Pruritus",208,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 21, 2025\nStudy Completion: June 13, 2025"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05131477","Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study","• Eczema\n• Atopic Dermatitis",350,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 12, 2023\nStudy Completion: May 20, 2024"]
["Immuno-inflammation","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05107115","Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine","• Chronic Spontaneous Urticaria",152,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 23, 2023\nStudy Completion: February 20, 2024"]
["Immuno-inflammation","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05104892","Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma","• Asthma",192,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 8, 2024\nStudy Completion: February 6, 2024"]
["Immuno-inflammation","frexalimab (anti-CD40L mAb)","\nPhase 2\n","NCT05039840","Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus","• Systemic Lupus Erythematosus",116,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 26, 2024\nStudy Completion: May 20, 2024"]
["Immuno-inflammation","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05018806","Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis","• Atopic Dermatitis",120,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 2024\nStudy Completion: February 2024"]
["Immuno-inflammation","SAR444727 (BTK inhibitor - topical)","\nPhase 2\n","NCT04992546","Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis","• Atopic Dermatitis",40,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 24, 2023\nStudy Completion: February 24, 2023"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT05526521","A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants\n>=2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) or Chronic Inducible Cold Urticaria (CICU) (LIBERTY-CSU/CINDU CUPIDKids)","• Chronic Spontaneous Urticaria\n• Chronic Cold Urticaria",24,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 29, 2024\nStudy Completion: June 7, 2024"]
["Immuno-inflammation","Oral TNF inhibitor","\nPhase 1\n","NCT05453942","A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis","• Psoriasis",36,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: February 16, 2023\nStudy Completion: February 16, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","• Multiple Myeloma",56,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 15, 2024\nStudy Completion: February 15, 2024"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT03733717","Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","• Multiple Myeloma",25,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 6, 2020\nStudy Completion: May 3, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03617731","Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","• Multiple Myeloma",662,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2025\nStudy Completion: December 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03319667","Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant","• Plasma Cell Myeloma",475,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 1, 2022\nStudy Completion: June 30, 2027"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03275285","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",302,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 21, 2022\nStudy Completion: February 7, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",307,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 22, 2018\nStudy Completion: July 28, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT02812706","Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients","• Multiple Myeloma",32,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 31, 2018\nStudy Completion: October 10, 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","• Plasma Cell Myeloma",90,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 2026\nStudy Completion: July 2026"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT01749969","SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","• Plasma Cell Myeloma",60,"• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 3, 2023\nStudy Completion: August 3, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT01084252","Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","• Hematological Malignancy",351,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 21, 2018\nStudy Completion: August 3, 2023"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04394624","SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)","• Non-small Cell Lung Cancer Metastatic",36,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 31, 2022\nStudy Completion: September 1, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04270409","A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma","• Plasma Cell Myeloma",300,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 1, 2028\nStudy Completion: October 1, 2033"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 3\n","NCT04154956","SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non- small Cell Lung Cancer Patients","• Non-small Cell Lung Cancer Metastatic",554,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 16, 2025\nStudy Completion: February 17, 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 2\n","NCT03860844","Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","• Acute Lymphoblastic Leukemia\n• Acute Myeloid Leukemia",96,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 31, 2023\nStudy Completion: August 31, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03769181","A Study of Isatuximab-based Therapy in Participants With Lymphoma","• Lymphoma",58,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 10, 2022\nStudy Completion: November 10, 2022"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03409614","Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","• Non-small Cell Lung Cancer",790,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 28, 2023\nStudy Completion: July 28, 2023"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 1\n","NCT03324113","Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","• Neoplasm Malignant",81,"• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 14, 2022\nStudy Completion: March 31, 2023"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03257267","Study of Cemiplimab in Adults With Cervical Cancer","• Squamous Cell Carcinoma (SCC)\n• Recurrent or Metastatic, Platinum-refractory Cervical Cancer",608,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 15, 2021\nStudy Completion: July 9, 2023"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03088540","Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","• Carcinoma#Non-Small-Cell Lung\n• Lung Carcinomas, Non- Small-Cell\n• Non-small-cell Lung Carcinoma\n• Nonsmall Cell Lung Cancer",712,"• Allocation: Randomized\n• Intervention Model: Crossover Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 30, 2024\nStudy Completion: April 30, 2024"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\n• Phase 1\n• Phase 2\n","NCT02187848","Evaluation of SAR408701 in Patients With Advanced Solid Tumors","• Neoplasm Malignant",263,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2023\nStudy Completion: March 31, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04751877","Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and\nDexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (# 65; < 80 Years).","• Multiple Myeloma\n• Myeloma",270,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2, 2024\nStudy Completion: August 17, 2027"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04659603","Tusamitamab Ravtansine in Patients With CEACAM5-positive Advanced Solid Tumors","• Breast Cancer Metastatic\n• Pancreatic Carcinoma Metastatic",64,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 13, 2025\nStudy Completion: January 13, 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","• Plasma Cell Myeloma Refractory",72,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 7, 2028\nStudy Completion: June 7, 2028"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04524689","Tusamitamab Ravtansine (SAR408701)  in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701)  in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)","• Non-squamous Non-small- cell Lung Cancer (NSQ NSCLC)",120,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 21, 2023\nStudy Completion: August 6, 2024"]
["Oncology","SAR442720 (SHP2 inhibitor)","\n• Phase 1\n• Phase 2\n","NCT04418661","Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies","• Metastatic Neoplasm",133,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 15, 2025\nStudy Completion: July 15, 2025"]
["Oncology","SAR442257 (anti CD38xCD28xCD3 trispecific mAb)","\nPhase 1\n","NCT04401020","First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","• Neoplasm Malignant",57,"• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2024\nStudy Completion: June 5, 2025"]
["Oncology","SAR444245 (Non-alpha IL-2 Synthorin)","\n• Phase 1\n• Phase 2\n","NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors","• Metastasis",300,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 14, 2023\nStudy Completion: August 14, 2023"]
["Oncology","SAR441000 (Cytokine mRNA)","\nPhase 1\n","NCT03871348","A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors","• Metastatic Neoplasm",77,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 25, 2022\nStudy Completion: March 29, 2024"]
["Oncology","alomfilimab (SAR445256/Anti-ICOS mAb)","\n• Phase 1\n• Phase 2\n","NCT03829501","Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer","• Squamous Cell Carcinoma of Head and Neck\n• Non-small Cell Lung Cancer\n• Hepatocellular Carcinoma\n• Esophageal Cancer\n• Gastric Cancer\n• Melanoma\n• Renal Cell Carcinoma\n• Pancreatic Cancer\n• Cervical Cancer\n• Triple Negative Breast Cancer\n• Advanced Cancer\n• Metastatic Cancer",280,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 2024\nStudy Completion: November 2024"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 1\n","NCT03634982","Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","• Solid Tumors",133,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2023\nStudy Completion: May 31, 2023"]
["Oncology","SAR443579 (anti-NKp46/CD123) ","\n• Phase 1\n• Phase 2\n","NCT05086315","First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR- MDS)","• Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome",82,"• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 5, 2024\nStudy Completion: April 20, 2026"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT05071053","Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in\nPretreated Participants With Gastric Cancer","• Adenocarcinoma Gastric\n• Gastrooesophageal Cancer",38,"• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 20, 2023\nStudy Completion: June 1, 2023"]
["Oncology","SAR444245 (Non-alpha IL-2 Synthorin)","\nPhase 2\n","NCT05061420","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)","• Squamous Cell Carcinoma of Head and Neck",120,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 27, 2024\nStudy Completion: February 1, 2024"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 2\n","NCT05054725","Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies","• Non-Small Cell Lung Cancer",46,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2023\nStudy Completion: January 19, 2024"]
["Oncology","SAR443216 (anti-CD3xCD28xHer2 trispecific mAb)","\nPhase 1\n","NCT05013554","Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/ Refractory HER2 Expressing Solid Tumors","• Neoplasm Malignant\n• Breast Cancer\n• Lung Neoplasm Malignant\n• Gastric Cancer\n• Neoplasm",200,"• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 23, 2025\nStudy Completion: June 23, 2025"]
["Oncology","SAR444245 (Non-alpha IL-2 Synthorin)","\nPhase 2\n","NCT04914897","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)","• Pleural Mesothelioma\n• Non-small Cell Lung Cancer",160,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 9, 2024\nStudy Completion: February 9, 2024"]
["Oncology","SAR444245 (Non-alpha IL-2 Synthorin)","\n• Phase 1\n• Phase 2\n","NCT04913220","A Study of SAR444245 Combined With Cemiplimab for the Treatment of\nParticipants With Various Advanced Skin Cancers (Pegathor Skin 201)","• Malignant Melanoma\n• Squamous Cell Carcinoma of Skin",80,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 7, 2024\nStudy Completion: June 5, 2026"]
["Oncology","SAR444881 (anti-ILT2 mAb)","\n• Phase 1\n• Phase 2\n","NCT04717375","Study of BND-22 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors","• Cancer",130,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2023\nStudy Completion: January 2024"]
["Oncology","SAR445710 (anti-PD-L1/IL-15 fusion protein)","\nPhase 1\n","NCT04242147","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.","• Advanced Solid Tumor",50,"• Allocation: Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 8, 2023\nStudy Completion: August 8, 2023"]
["Oncology","SAR445419 (NK-cell-based immunotherapy)","\nPhase 1\n","NCT04220684","Ph1 Trial Test Safety of IL-21 NK Cells for Induction of R/R AML","• Allogeneic Stem Cell Transplant Recipient\n• Blasts 10 Percent or More of Bone Marrow Nucleated Cells\n• Recurrent Acute Myeloid Leukemia\n• Refractory Acute Myeloid Leukemia",30,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 31, 2022\nStudy Completion: December 31, 2022"]
["Oncology","Anti-GPC3/TCR Nanobody VHH","\n• Phase 1\n• Phase 2\n","NCT05450562","Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors","• Neoplasm",106,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 11, 2029\nStudy Completion: May 11, 2029"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT05405166","SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","• Plasma Cell Myeloma Recurrent",534,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 23, 2024\nStudy Completion: October 23, 2026"]
["Oncology","SAR446309 (HER2 T-Cell engager)","\nPhase 1\n","NCT05356741","To Access the Safety and Effects of Intravenous Administration of AMX 818 Alone and in Combination With\nPembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2- Expressing Cancers","• Locally Advanced or Metastatic HER2-Expressing Cancers",560,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 9, 2026\nStudy Completion: December 9, 2026"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT05245071","Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA","• Non-squamous Non-small Cell Lung Cancer",38,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 2, 2024\nStudy Completion: May 24, 2024"]
["Oncology","SAR444245 (Non-alpha IL-2 Synthorin)","\nPhase 2\n","NCT05179603","A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]","• Classic Hodgkin Lymphoma\n• Diffuse Large B-cell Lymphoma",50,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 28, 2025\nStudy Completion: May 29, 2025"]
["Oncology","SAR445088 (Complement C1S inhibitor)","\nPhase 2\n","NCT05156710","BIVV020 in Prevention and Treatment of Antibody-mediated Rejection (AMR)","• Transplant Rejection",54,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 14, 2024\nStudy Completion: May 26, 2025"]
["Oncology","SAR444245 (Non-alpha IL-2 Synthorin)","\nPhase 2\n","NCT05104567","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With\nGastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)","• Oesophageal Squamous Cell Carcinoma\n• Gastric Cancer\n• Hepatocellular Carcinoma\n• Colorectal Cancer\n• Oseophageal Adenocarcinoma",280,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 23, 2024\nStudy Completion: January 23, 2024"]
["Neurology","SAR443820 (RIPK1 inhibitor central)","\nPhase 2\n","NCT05237284","Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)","• Amyotrophic Lateral Sclerosis",261,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 5, 2023\nStudy Completion: August 12, 2025"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT05132569","Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis","• Myasthenia Gravis",154,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: November 25, 2024\nStudy Completion: December 22, 2026"]
["Neurology","frexalimab (anti-CD40L mAb)","\nPhase 2\n","NCT04879628","Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis","• Multiple Sclerosis",129,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 22, 2022\nStudy Completion: March 7, 2024"]
["Neurology","SAR445088 (Complement C1S inhibitor)","\nPhase 2\n","NCT04658472","Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","• Chronic Inflammatory Demyelinating Polyradiculoneuropathy",100,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 2, 2024\nStudy Completion: August 2, 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Primary Progressive Multiple Sclerosis",990,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Secondary Progressive Multiple Sclerosis",1290,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410991","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2023\nStudy Completion: August 2023"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410978","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 6, 2023\nStudy Completion: September 6, 2023"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 2\n","NCT03996291","Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis","• Relapsing Multiple Sclerosis",125,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2025\nStudy Completion: April 2025"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT05280548","A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease","• Fabry's Disease",90,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2025\nStudy Completion: August 4, 2026"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT05222906","Study to Evaluate the Efficacy and Safety\nof Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3","• Gaucher's Disease Type III",40,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: September 2025"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT05206773","A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Adult Participants With Fabry Disease","• Fabry Disease",114,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: November 21, 2024\nStudy Completion: January 5, 2026"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT04221451","A Multinational, Randomized, Double- blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics,\nPharmacokinetics, and Safety of Venglustat in Late-onset GM2","• Tay-Sachs Disease Sandhoff Disease",74,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 25, 2026\nStudy Completion: February 25, 2026"]
["Rare diseases","Nexviazyme (Enzyme Replacement Therapy - GAA) ","\nPhase 2\n","NCT03019406","A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","• Glycogen Storage Disease Type II-Pompe's Disease",22,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 30, 2019\nStudy Completion: December 2024"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 2\n","NCT02843035","Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","• Gaucher Disease Type 1\n• Gaucher Disease Type 3",13,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 30, 2025\nStudy Completion: September 30, 2025"]
["Rare diseases","Nexviazyme (Enzyme Replacement Therapy - GAA) ","\nPhase 3\n","NCT02782741","Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","• Glycogen Storage Disease Type II;Pompe's Disease",100,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 19, 2020\nStudy Completion: May 2023"]
["Rare diseases","Nexviazyme (Enzyme Replacement Therapy - GAA) ","\n• Phase 2\n• Phase 3\n","NCT02032524","Avalglucosidase Alfa Extension Study","• Glycogen Storage Disease Type II Pompe Disease",19,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 10, 2022\nStudy Completion: November 10, 2022"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05002777","Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)","• Warm Autoimmune Hemolytic Anemia (wAIHA)",20,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 20, 2023\nStudy Completion: June 10, 2024"]
["Rare blood disorders","SAR445088 (Complement C1S inhibitor)","\nPhase 1\n","NCT04802057","Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With BIVV020","• Autoimmune Haemolytic Anaemia",4,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 8, 2028\nStudy Completion: December 8, 2028"]
["Rare blood disorders","ALTUVIIIO (rFVIIIFc - vWF - XTEN)","\nPhase 1\n","NCT04770935","To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)","• Von Willebrand's Disease (VWD)",9,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Other","Primary Completion: May 7, 2023\nStudy Completion: May 25, 2023"]
["Rare blood disorders","ALTUVIIIO (rFVIIIFc - vWF - XTEN)","\nPhase 3\n","NCT04759131","Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","• Hemophilia A",75,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 1, 2023\nStudy Completion: February 1, 2023"]
["Rare blood disorders","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04661033","Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)","• Warm Autoimmune Hemolytic Anemia (wAIHA)",23,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 22, 2024\nStudy Completion: July 22, 2024"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\nPhase 3\n","NCT04562766","Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia",224,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 2023\nStudy Completion: June 2025"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\n• Phase 2\n• Phase 3\n","NCT03974113","Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B","• Hemophilia",32,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 9, 2023\nStudy Completion: December 2026"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03754790","Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","• Hemophilia",355,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 19, 2026\nStudy Completion: October 19, 2026"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03395210","A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia\n• Immune Thrombocytopenic Purpura",81,"• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2, 2023\nStudy Completion: March 19, 2024"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\n• Phase 1\n• Phase 2\n","NCT02554773","An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B","• Hemophilia A\n• Hemophilia B",37,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 4, 2023\nStudy Completion: April 4, 2023"]
["Vaccines","SP0202 (Pneumococcal Next Generation  Conjugate  Vaccine)","\nPhase 2\n","NCT04398706","Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","• Pneumococcal Immunisation\n• Diphtheria Immunisation\n• Tetanus Immunisation\n• Pertussis Immunisation\n• Hepatitis B Immunisation\n• Haemophilus Influenzae Type b Immunisation\n• Polio Immunisation\n• Measles Immunisation\n• Rubella Immunisation\n• Varicella Immunisation\n• Mumps Immunisation",840,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: October 13, 2023\nStudy Completion: October 13, 2023"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT04143061","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa","• Healthy Volunteers (Meningococcal Infection)",1332,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 14, 2023\nStudy Completion: September 14, 2023"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT04142242","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","• Meningococcal Infection (Healthy Volunteers)",471,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: April 1, 2020\nStudy Completion: May 25, 2022"]
["Vaccines","VRVg (Purified vero rabies vaccine)","\nPhase 3\n","NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","• Rabies (Healthy Volunteers)",1700,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 15, 2020\nStudy Completion: October 3, 2025"]
["Vaccines","VRVg (Purified vero rabies vaccine)","\nPhase 3\n","NCT03965962","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","• Rabies (Healthy Volunteers)",640,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: December 22, 2020\nStudy Completion: July 1, 2021"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT03869866","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","• Healthy Volunteers (Meningococcal Infection)",260,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: March 17, 2022\nStudy Completion: March 17, 2022"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","• Healthy Volunteers (Meningococcal Infection)",1070,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: October 27, 2023\nStudy Completion: October 27, 2023"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT03630705","Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","• Healthy Volunteers (Meningococcal Infection)",525,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: February 18, 2022\nStudy Completion: February 18, 2022"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","• Meningococcal Infections",1652,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: October 20, 2023\nStudy Completion: October 20, 2023"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","• Healthy Volunteers (Meningococcal Infection)",2628,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: October 11, 2023\nStudy Completion: October 11, 2023"]
["Vaccines","SP0218 (Yellow fever vaccine)","\nPhase 2\n","NCT04942210","Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA","• Yellow Fever (Healthy Volunteers)",567,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: June 24, 2022\nStudy Completion: January 31, 2027"]
["Vaccines","Vidprevtyn (COVID-19 recombinant baculovirus vaccine )","\nPhase 3\n","NCT04904549","Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older","• COVID-19",23726,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: June 3, 2024\nStudy Completion: June 3, 2024"]
["Vaccines","SP0230 (Multicomponent meningitis B vaccine )","\n• Phase 1\n• Phase 2\n","NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","• Meningococcal Immunisation",1800,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 29, 2025\nStudy Completion: October 29, 2025"]
["Vaccines","Vidprevtyn (COVID-19 recombinant baculovirus vaccine )","\n• Phase 2\n• Phase 3\n","NCT04762680","Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older","• COVID-19",3385,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: July 19, 2023\nStudy Completion: July 19, 2023"]
["Vaccines","VRVg (Purified vero rabies vaccine)","\nPhase 3\n","NCT04594551","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adults in Thaïland","• Rabies (Healthy Volunteers)",201,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: June 23, 2021\nStudy Completion: June 23, 2021"]
["Vaccines","Vidprevtyn (COVID-19 recombinant baculovirus vaccine )","\n• Phase 1\n• Phase 2\n","NCT04537208","Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older","• COVID-19 (Healthy Volunteers)",442,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: November 19, 2021\nStudy Completion: November 19, 2021"]
["Vaccines","SP0125 (Live-Attenuated RSV Vaccine)","\nPhase 2\n","NCT04491877","Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","• Respiratory Syncytial Virus Infection",300,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: April 27, 2023\nStudy Completion: April 27, 2023"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT04490018","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","• Meningococcal Infection (Healthy Volunteers)",464,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 11, 2022\nStudy Completion: May 11, 2022"]
["Vaccines","VRVg (Purified vero rabies vaccine)","\nPhase 3\n","NCT04478084","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","• Rabies (Healthy Volunteers)",403,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 19, 2022\nStudy Completion: July 21, 2022"]
["Vaccines","SP0273 (mRNA Vaccine)","\n• Phase 1\n• Phase 2\n","NCT05553301","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","• Influenza Immunization",560,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: January 19, 2024\nStudy Completion: January 19, 2024"]
["Vaccines","Fluzone HD (SP0178)","\nPhase 3\n","NCT05144945","Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant\nInfluenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","• Influenza (Healthy Volunteers)",301,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 14, 2022\nStudy Completion: September 14, 2022"]
["Vaccines","MenQuadfi (Meningococcal (A,C,Y,W) conjugate vaccine)","\nPhase 3\n","NCT04936685","Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","• Meningococcal Infection",500," \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: February 3, 2023\nStudy Completion: December 26, 2027"]